How Bicycle Health, Ophelia, Boulder Care, Pelago (Quit Genius), Groups Recover Together, Eleanor Health, Workit Health, Brightside, Talkiatry.
AI-native opioid-use-disorder-OUD, substance-use-disorder-SUD, medication-assisted-treatment-MAT, medication-for-opioid-use-disorder-MOUD, buprenorphine-Suboxone-Sublocade-Brixadi, methadone-opioid-treatment-program-OTP, naltrexone-Vivitrol-extended-release, naloxone-Narcan-OTC-Mar-2023, Zurnai-nalmefene-FDA-Aug-2024, alcohol-use-disorder-AUD, acamprosate-Campral, disulfiram-Antabuse, naltrexone-oral, gabapentin, topiramate, stimulant-use-disorder-methamphetamine-cocaine-crack, contingency-management-CM, cognitive-behavioral-therapy-CBT, motivational-interviewing-MI, medication-management, peer-recovery-support-specialist-PRSS, intensive-outpatient-IOP, partial-hospitalization-PHP, residential, American-Society-Addiction-Medicine-ASAM-Criteria-4th-Edition-Oct-2023, Screening-Brief-Intervention-Referral-to-Treatment-SBIRT, harm-reduction, syringe-services-programs-SSPs, fentanyl-test-strips, xylazine-tranq-DEA-detection, behavioral-health-telepsychiatry, psychiatry-collaborative-care-model-CoCM, measurement-based-care-MBC, PHQ-9, GAD-7, AUDIT, DAST-10, Columbia-Suicide-Severity-Rating-Scale-C-SSRS, Brief-Addiction-Monitor-BAM is one of the highest-signal AI-behavioral-health, digital-health, specialty-pharma, Medicaid-managed-care categories for 2026 — validated by Bicycle-Health $50M-Series-B-Aug-2021-InterAlpen, Ophelia $50M-Series-B-Feb-2022-Tiger, Boulder-Care $36M-Series-B-May-2023-Goodwater-Qiming, Pelago-Quit-Genius $57M-Series-B-Aug-2022-Softbank-Vision-2, Groups-Recover-Together $60M-Series-D-Oct-2021-Oak-HC-FT, Eleanor-Health $50M-Series-C-Jan-2022-General-Catalyst, Workit-Health $118M-Series-C-Feb-2022-Insight, Brightside-Health $50M-Series-B-Nov-2021-Andreessen-a16z, Talkiatry $130M-Series-C-Apr-2024-Andreessen-a16z-bio-health-Andreessen, Headway $125M-Series-C-Jul-2023-Spark-Capital, Grow-Therapy $88M-Series-C-Sep-2024-Sequoia-SignalFire, Rula-Health $50M-Series-C-2023, SonderMind $150M-Series-C-Dec-2021-Drive-Capital, Alma $130M-Series-D-Nov-2022-Insight-Cigna, Path-Mental-Health $25M-Series-A-Oct-2023-Andreessen, Charlie-Health-$150M-Series-B-2022-adj, BasePoint-Academy, Cerebral-recovery-post-Adderall, Done-recovery-Adderall, Amazon-Clinic, Included-Health-Grand-Rounds, Lyra-Health $235M-Series-G-Jan-2022-Coatue-Sands, Modern-Health $74M-Series-D-Feb-2021-Founders-Fund, Spring-Health $190M-Series-D-Apr-2024-Generation-a16z-Kinnevik as the credible-scale AI-SUD-behavioral-health-telehealth stack. Founders here underwrite on DEA-controlled-substance-telemedicine-extension, SAMHSA, 42-CFR-Part-2-Final-Rule-Feb-2024, MHPAEA-Final-Rule-Sep-2024, ASAM-Criteria-4th-Edition-Oct-2023, HIPAA, state-medical-board, Medicaid-managed-care-MCO, Medicare-Advantage-MA, commercial-in-network benchmark — not vanity 'AI-therapy' or 'digital-recovery' claims without a DEA-registered-provider network, X-waiver-elimination-MAT-Act-Dec-2022, or measurable retention, engagement, urine-drug-screen-negative outcomes.
Four unlocks: (1) DEA-Third-Temporary-Extension-Nov-2024-through-Dec-31-2025 preserved controlled-substance-telemedicine (Suboxone-buprenorphine, Adderall-stimulant, Xanax-benzo) prescribing without an in-person exam, and the expected DEA-Special-Registration-Final-Rule-2025 will finally create a permanent post-Ryan-Haight-Act framework — collapsing 4+ years of PHE-waiver uncertainty for Bicycle-Health, Ophelia, Boulder, Workit, Talkiatry, Brightside, Done-Health-Cerebral-post-DEA business models. Combined with MAT-Act-Dec-2022 elimination of the X-waiver, 8-hour-training-Jun-2023, the addressable prescriber base for buprenorphine expanded from ~90k X-waivered providers to ~1.8M DEA-registered practitioners. (2) SAMHSA-42-CFR-Part-8-Final-Rule-Feb-2024 permanently codified methadone take-home flexibilities, telemedicine methadone induction, audio-only buprenorphine — the first material OTP modernization since 2001. (3) 42-CFR-Part-2-Final-Rule-Feb-8-2024 aligned SUD confidentiality with HIPAA via a single-consent model (compliance Feb-16-2026) — unblocking care coordination, HIE, TEFCA integration, and value-based-care contracting that Part-2 legacy segmentation historically prevented. (4) MHPAEA-Final-Rule-Sep-9-2024 (effective plan years Jan-1-2025 and Jan-1-2026) hard-gated Non-Quantitative-Treatment-Limitations-NQTL Comparative-Analysis, network-composition, prior-authorization, medical-necessity, reimbursement-rate parity — forcing Elevance-Anthem, Aetna-CVS, Cigna, United-Optum, Humana, BCBS, Molina, Centene to materially expand in-network behavioral-health, SUD provider networks, reimbursement rates, and telepsychiatry access. This is a $200B+ behavioral-health, SUD spend re-underwrite catalyzed by a single regulatory rule.
Pre-seed / Seed $1-6M for first-DEA-registered-provider-network, first-state-medical-board-multi-state, first-CARF-JCAHO-accreditation, first-Medicaid-managed-care-contract, first-42-CFR-Part-2-BAA, first-ASAM-CONTINUUM-integration, first-Contingency-Management-Medicaid-1115-waiver (Affect-Therapeutics $16M-A-Oak-HC-FT-Redesign, DynamiCare early, Bend-Health, Cartwheel, Little-Otter). Series A/B $30-130M for DEA-multi-state, Interstate-Medical-Licensure-Compact-40-state, PSYPACT-40-state, Counseling-Compact-30-state, SAMHSA-OTP, Medicaid-MCO, Medicare-Advantage, commercial-in-network, measurement-based-care-outcomes-JAMA-Psychiatry-published, MHPAEA-parity-audit-ready-scale (Bicycle-Health $50M-B-Aug-2021-InterAlpen, Ophelia $50M-B-Feb-2022-Tiger-General-Catalyst, Boulder $36M-B-May-2023-Goodwater-Qiming, Workit $118M-C-Feb-2022-Insight, Groups $60M-D-Oct-2021-Oak-HC-FT, Eleanor $50M-C-Jan-2022-General-Catalyst, Pelago-Quit-Genius $57M-B-Aug-2022-Softbank, Brightside $50M-B-Nov-2021-a16z, Talkiatry $130M-C-Apr-2024-a16z, Headway $125M-C-Jul-2023-Spark, Grow-Therapy $88M-C-Sep-2024-Sequoia-SignalFire, Rula $50M-C-2023, Alma $130M-D-Nov-2022-Insight-Cigna, Charlie-Health $150M-B-2022-adj, Brightline $105M-C-Apr-2022-KKR-Oak-HC-FT). Growth, PE, strategic $150M-$3.3B — SonderMind $150M-C-Dec-2021-Drive, Lyra-Health $235M-G-Jan-2022-Coatue-Sands-$5.9B, Modern-Health $74M-D-Feb-2021-Founders-Fund, Spring-Health $190M-D-Apr-2024-Generation-a16z-Kinnevik-$3.3B, Ginger-Headspace-merger-$3B-Aug-2021, BetterHelp-Teladoc, Talkspace $NASDAQ:TALK. Non-dilutive material — SAMHSA-State-Opioid-Response-SOR-block-grant, Tribal-Opioid-Response-TOR, Bipartisan-Safer-Communities-Act-Jun-2022, SUPPORT-Act-2018, CARA-2016, NIDA-National-Institute-Drug-Abuse-HEAL-Initiative, NIMH-mental-health, opioid-settlement-Distributor-J&J-Kroger-Walmart-CVS-Walgreens-Rite-Aid-$50B-2022-2024, Sackler-Purdue-SCOTUS-Jun-2024 State-Opioid-Settlement-Board.
Overclaiming retention, urine-drug-screen-negative, engagement, reduced-overdose, reduced-mortality, PHQ-9-GAD-7-response without DEA-registered-provider-multi-state, SAMHSA-42-CFR-Part-8-OTP, 42-CFR-Part-2-Final-Rule-Feb-2024-Apr-2024-Feb-2026-compliance, MHPAEA-Final-Rule-Sep-2024, ASAM-Criteria-4th-Edition-Oct-2023, HIPAA-BAA, peer-reviewed JAMA-Psychiatry, AJP, Journal-Substance-Abuse-Treatment, Addiction, Drug-Alcohol-Dependence, NEJM, Lancet-Psychiatry multi-center validation — post-DEA-Third-Extension-Dec-2025, MAT-Act-X-waiver-Dec-2022, SAMHSA-OTP-Feb-2024, 42-CFR-Part-2-Feb-2024, MHPAEA-Sep-2024, Cerebral-DEA-2022, Done-Health-DEA-Jun-2024-charges, Pear-Therapeutics-Chapter-11-Apr-2023-lessons credible-scale bar, operators without DEA, SAMHSA, 42-CFR-Part-2, MHPAEA-NQTL, ASAM, peer-reviewed, Medicaid-managed-care-MCO, Medicare-Advantage, commercial-in-network audit trail get flagged by a16z-Bio-Health, General-Catalyst, Oak-HC-FT, Tiger, Softbank, Insight, Goodwater, Spark, Sequoia, SignalFire, Drive, Coatue, Founders-Fund, Generation, Kinnevik, KKR diligence within 12-18 months. Underestimating DEA, state-medical-board, Wire-Fraud, Anti-Kickback-Statute-AKS, Stark-Law, False-Claims-Act-FCA, Controlled-Substances-Act-CSA legal risk — Cerebral-DEA-2022, Done-Health-DEA-DOJ-Adderall-Jun-2024-federal-indictment-CEO-CMO-arrested, Pear-Therapeutics-Chapter-11, Ontrak-DOJ-Feb-2023, Prescription-Digital-Therapeutic-CMS-non-coverage-2022, Adderall-shortage-FDA-Oct-2022-Nov-2024-lesson demonstrate telemedicine-controlled-substance is the highest-litigation-risk category in digital health. Building yet-another therapist-marketplace or Suboxone-telehealth in a market where Bicycle-Health, Ophelia, Boulder, Workit, Groups, Eleanor, Talkiatry, Brightside, Headway, Grow-Therapy, Rula, Alma, SonderMind, Lyra, Spring, Modern already have deep in-network payer, Medicaid-MCO, Medicare-Advantage, Fortune-500-employer contracts, without a defensible ASAM-Level, condition-specific (stimulant-CM, AUD, adolescent-IOP, rural-Medicaid, criminal-justice-diversion, perinatal-SUD, LGBTQ-affirming, tribal) or payer-vertical (Medicaid-1115-CM-waiver, Medicare-Advantage-supplemental-benefit, VA-Community-Care, IHS) wedge.
Investor directory · Fundraising library · Articles A–Z · Company funding database
